PRIVIA HEALTH GROUP INC (PRVA) Stock Fundamental Analysis
USA - NASDAQ:PRVA - US74276R1023 - Common Stock
25.53 USD
0 (0%)
25.53 USD
0 (0%)
PRVA gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 101 industry peers in the Health Care Providers & Services industry. No worries on liquidiy or solvency for PRVA as it has an excellent financial health rating, but there are worries on the profitability. PRVA is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year PRVA was profitable.
In the past year PRVA had a positive cash flow from operations.
In multiple years PRVA reported negative net income over the last 5 years.
PRVA had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
PRVA has a Return On Assets of 1.17%. This is comparable to the rest of the industry: PRVA outperforms 53.47% of its industry peers.
With a Return On Equity value of 2.17%, PRVA perfoms like the industry average, outperforming 55.45% of the companies in the same industry.
The Return On Invested Capital of PRVA (1.78%) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.17% | ||
| ROE | 2.17% | ||
| ROIC | 1.78% |
ROA(3y)0.83%
ROA(5y)-3.09%
ROE(3y)1.55%
ROE(5y)-3.63%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With a Profit Margin value of 0.78%, PRVA perfoms like the industry average, outperforming 53.47% of the companies in the same industry.
In the last couple of years the Profit Margin of PRVA has declined.
PRVA has a Operating Margin (1.03%) which is in line with its industry peers.
PRVA's Operating Margin has declined in the last couple of years.
PRVA has a Gross Margin of 9.96%. This is in the lower half of the industry: PRVA underperforms 73.27% of its industry peers.
In the last couple of years the Gross Margin of PRVA has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 1.03% | ||
| PM (TTM) | 0.78% | ||
| GM | 9.96% |
OM growth 3YN/A
OM growth 5Y-13.74%
PM growth 3YN/A
PM growth 5Y-4.5%
GM growth 3Y15.6%
GM growth 5Y3.18%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), PRVA is destroying value.
PRVA has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, PRVA has more shares outstanding
PRVA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
An Altman-Z score of 4.87 indicates that PRVA is not in any danger for bankruptcy at the moment.
With a decent Altman-Z score value of 4.87, PRVA is doing good in the industry, outperforming 79.21% of the companies in the same industry.
PRVA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 4.87 |
ROIC/WACC0.21
WACC8.66%
2.3 Liquidity
PRVA has a Current Ratio of 1.65. This is a normal value and indicates that PRVA is financially healthy and should not expect problems in meeting its short term obligations.
The Current ratio of PRVA (1.65) is comparable to the rest of the industry.
A Quick Ratio of 1.65 indicates that PRVA should not have too much problems paying its short term obligations.
Looking at the Quick ratio, with a value of 1.65, PRVA is in the better half of the industry, outperforming 60.40% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.65 | ||
| Quick Ratio | 1.65 |
3. Growth
3.1 Past
The earnings per share for PRVA have decreased by -8.33% in the last year.
The Earnings Per Share has been growing slightly by 7.43% on average over the past years.
Looking at the last year, PRVA shows a quite strong growth in Revenue. The Revenue has grown by 12.05% in the last year.
PRVA shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 17.17% yearly.
EPS 1Y (TTM)-8.33%
EPS 3YN/A
EPS 5Y7.43%
EPS Q2Q%-33.33%
Revenue 1Y (TTM)12.05%
Revenue growth 3Y21.58%
Revenue growth 5Y17.17%
Sales Q2Q%18.53%
3.2 Future
PRVA is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 59.10% yearly.
The Revenue is expected to grow by 2.27% on average over the next years.
EPS Next Y51.21%
EPS Next 2Y71.1%
EPS Next 3Y59.1%
EPS Next 5YN/A
Revenue Next Year15.55%
Revenue Next 2Y8.04%
Revenue Next 3Y6.75%
Revenue Next 5Y2.27%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 232.09, PRVA can be considered very expensive at the moment.
PRVA's Price/Earnings is on the same level as the industry average.
When comparing the Price/Earnings ratio of PRVA to the average of the S&P500 Index (27.40), we can say PRVA is valued expensively.
With a Price/Forward Earnings ratio of 79.28, PRVA can be considered very expensive at the moment.
Compared to the rest of the industry, the Price/Forward Earnings ratio of PRVA is on the same level as its industry peers.
The average S&P500 Price/Forward Earnings ratio is at 22.94. PRVA is valued rather expensively when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 232.09 | ||
| Fwd PE | 79.28 |
4.2 Price Multiples
PRVA's Enterprise Value to EBITDA ratio is a bit more expensive when compared to the industry. PRVA is more expensive than 62.38% of the companies in the same industry.
PRVA's Price/Free Cash Flow ratio is in line with the industry average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 32.35 | ||
| EV/EBITDA | 98.93 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
PRVA's earnings are expected to grow with 59.10% in the coming years. This may justify a more expensive valuation.
PEG (NY)4.53
PEG (5Y)31.22
EPS Next 2Y71.1%
EPS Next 3Y59.1%
5. Dividend
5.1 Amount
No dividends for PRVA!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
25.53
0 (0%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners97.09%
Inst Owner Change0.01%
Ins Owners1.85%
Ins Owner Change-0.11%
Market Cap3.13B
Analysts84.44
Price Target31.19 (22.17%)
Short Float %2.73%
Short Ratio3.41
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-49.4%
Min EPS beat(2)-60.96%
Max EPS beat(2)-37.83%
EPS beat(4)0
Avg EPS beat(4)-44.58%
Min EPS beat(4)-60.96%
Max EPS beat(4)-37.83%
EPS beat(8)0
Avg EPS beat(8)-41.13%
EPS beat(12)4
Avg EPS beat(12)50.02%
EPS beat(16)7
Avg EPS beat(16)58.25%
Revenue beat(2)2
Avg Revenue beat(2)3.24%
Min Revenue beat(2)0.75%
Max Revenue beat(2)5.73%
Revenue beat(4)4
Avg Revenue beat(4)3.97%
Min Revenue beat(4)0.75%
Max Revenue beat(4)7.92%
Revenue beat(8)8
Avg Revenue beat(8)3.27%
Revenue beat(12)9
Avg Revenue beat(12)-4.22%
Revenue beat(16)10
Avg Revenue beat(16)-9.82%
PT rev (1m)0%
PT rev (3m)-0.07%
EPS NQ rev (1m)1.32%
EPS NQ rev (3m)-13.58%
EPS NY rev (1m)0.79%
EPS NY rev (3m)-20.73%
Revenue NQ rev (1m)-7.7%
Revenue NQ rev (3m)-8.03%
Revenue NY rev (1m)-0.32%
Revenue NY rev (3m)3.39%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 232.09 | ||
| Fwd PE | 79.28 | ||
| P/S | 1.65 | ||
| P/FCF | 32.35 | ||
| P/OCF | 34.11 | ||
| P/B | 4.59 | ||
| P/tB | 9.2 | ||
| EV/EBITDA | 98.93 |
EPS(TTM)0.11
EY0.43%
EPS(NY)0.32
Fwd EY1.26%
FCF(TTM)0.79
FCFY3.09%
OCF(TTM)0.75
OCFY2.93%
SpS15.48
BVpS5.56
TBVpS2.77
PEG (NY)4.53
PEG (5Y)31.22
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.17% | ||
| ROE | 2.17% | ||
| ROCE | 2.66% | ||
| ROIC | 1.78% | ||
| ROICexc | 3.77% | ||
| ROICexgc | 251.71% | ||
| OM | 1.03% | ||
| PM (TTM) | 0.78% | ||
| GM | 9.96% | ||
| FCFM | 5.1% |
ROA(3y)0.83%
ROA(5y)-3.09%
ROE(3y)1.55%
ROE(5y)-3.63%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5Y-10.22%
OM growth 3YN/A
OM growth 5Y-13.74%
PM growth 3YN/A
PM growth 5Y-4.5%
GM growth 3Y15.6%
GM growth 5Y3.18%
F-Score5
Asset Turnover1.49
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | 77.53 | ||
| Cash Conversion | 331.3% | ||
| Profit Quality | 652.71% | ||
| Current Ratio | 1.65 | ||
| Quick Ratio | 1.65 | ||
| Altman-Z | 4.87 |
F-Score5
WACC8.66%
ROIC/WACC0.21
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-8.33%
EPS 3YN/A
EPS 5Y7.43%
EPS Q2Q%-33.33%
EPS Next Y51.21%
EPS Next 2Y71.1%
EPS Next 3Y59.1%
EPS Next 5YN/A
Revenue 1Y (TTM)12.05%
Revenue growth 3Y21.58%
Revenue growth 5Y17.17%
Sales Q2Q%18.53%
Revenue Next Year15.55%
Revenue Next 2Y8.04%
Revenue Next 3Y6.75%
Revenue Next 5Y2.27%
EBIT growth 1Y52.75%
EBIT growth 3YN/A
EBIT growth 5Y1.07%
EBIT Next Year534.36%
EBIT Next 3Y107.12%
EBIT Next 5Y64.83%
FCF growth 1Y145.73%
FCF growth 3Y26.09%
FCF growth 5Y42.42%
OCF growth 1Y132.44%
OCF growth 3Y25.67%
OCF growth 5Y35.01%